Decline in the AIDS and death rates in the EuroSIDA study: An observational study

Lancet

Volumn 362, Issue 9377, 2003, Pages 22-29

  Mocroft, A ^a   Ledergerber, B ^b   Katlama, C ^c   Kirk, O ^d   Reiss, P ^e   D'Arminio Monforte, A ^f   Knysz, B ^g   Dietrich, M ^h   Phillips, A N ^a   Lundgren, J D ^d  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d HVIDOVRE HOSPITAL   (Denmark)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF MILAN   (Italy)

^g UNIVERSITY OF WROC AW   (Poland)

^h BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARGENTINA; ARTICLE; CALCULATION; CONTROLLED STUDY; EUROPE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; INCIDENCE; INFECTION RISK; ISRAEL; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; POPULATION RESEARCH; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 0038162585     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)13802-0     Document Type: Article

References (31)

1. Mocroft A., Vella S., Benfield T.L., et al. Changing patterns of mortality across Europe in patients infected with HIV-1: EuroSIDA study group. Lancet. 352:1998;1725-1730.
2. Mocroft A., Katlama C., Johnson A.M., et al. AIDS across Europe, 1994-1998: The EuroSIDA study. Lancet. 356:2000;291-296.
3. Palella F.J., Delaney K.M., Moorman A.C., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 338:1998;853-860.
4. Egger M., Hirschel B., Francioli P., et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study - Swiss HIV Cohort Study. BMJ. 315:1997;1194-1199.
5. Kirk O., Mocroft A., Katzenstein T.L., et al. Changes in use of antiretroviral therapy in regions of Europe over time. AIDS. 12:1998;2031-2039.
6. Deeks S.G., Hecht F.M., Swanson M., et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS. 13:1999;35-43.
7. Lucas G.M., Chaisson R.E., Moore R.D. Highly active antiretroviral therapy in a large urban clinic: risk factors for virological failure and adverse drug reactions. Ann Intern Med. 131:1999;81-87.
8. Paredes R., Mocroft A., Kirk O., et al. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy. Arch Intern Med. 160:2000;1123-1132.
9. British HIV association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med. 2:2001;276-313.
10. Yeni P.G., Hammer S.M., Carpenter C.C.J., et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS society - USA panel. JAMA. 288:2002;222-235.
11. Lundgren J.D., Phillips A.N., Vella S., et al. Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. J Acquir Immun Defic Syndr Hum Retrovirol. 16:1997;153-160.
12. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 41:1992;1-19.
13. http://www.cphiv.dk/eurosida/Documents/EuroSIDA_2002a.pdf . (accessed April 9, 2003).
14. Egger M., May M., Chene G., et al. Prognosis of HIV-1 infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 360:2002;119-129.
15. Le Moing V., Thiebaut R., Chene G., et al. Predictors of long term increase in CD4 cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen. J Infect Dis. 185:2002;471-480.
16. Flandre P., Raffi F., Descamps D., et al. Final analysis of the Trilege induction-maintenance trial: results at 18 months. AIDS. 16:2002;561-568.
17. Piketty C., Weiss L., Thomas F., et al. Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. J Infect Dis. 183:2001;1328-1335.
18. 6 cells/L. AIDS. 14:2000;1147-1153.
19. Sterling T.R., Chaisson R.E., Moore R.D. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS. 15:2001;2251-2257.
20. Lundgren J.D., Mocroft A., Gatell J.M., et al. A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study. J Infect Dis. 185:2002;178-187.
21. Durant J., Clevenbergh P., Halfon P., et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet. 353:1999;2195-2199.
22. Hirsch M.S., Brun-Vezinet F., D'Aquila R.T., et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society - USA panel. JAMA. 283:2000;2417-2426.
23. Yeni P., Hammer S.M., Carpenter C.C.J., et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the international AIDS society - USA panel. JAMA. 288:2002;222-235.
24. Ledergerber B., Egger M., Opravil M., et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet. 353:1999;863-868.
25. Grulich A.E., Li Y., McDonald A., et al. Rates of non-AIDS defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS. 16:2002;1155-1161.
26. Martinez E., Mocroft A., Garcia-Viejo M.A., et al. Risk of lipodystrophy in HIV-1 infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 357:2001;592-598.
27. Selik R.M., Byers R.H., Dworkin M.S. Trends in diseases reported on US death certificates that mentioned HIV infection, 1987-1999. J Acquir Immun Defic Syndr Hum Retrovirol. 29:2002;378-387.
28. Mocroft A., Brettle R., Blaxhult A., et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS. 16:2002;1-9.
29. Benson C.A., Deeks S.G., Brun S.C., et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse transcriptase inhibitors in human immunodeficiency virus type-1 infected protease inhibitor-experienced patients. J Infect Dis. 185:2002;599-607.
30. Miller V., Phillips A.N., Clotet B., et al. Association of viral load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts. J Infect Dis. 186:2002;189-197.
31. Hogg R.S., Heath K.V., Yip B., et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 279:1998;450-454.